Dialysis Risk Prediction and Treatment Effect Estimation for AKI patients using Longitudinal Electronic Health Records

πŸ“… 2026-04-27
πŸ“ˆ Citations: 0
✨ Influential: 0
πŸ“„ PDF

career value

153K/year
πŸ€– AI Summary
This study addresses the prediction of progression to dialysis or end-stage kidney disease among patients with acute kidney injury (AKI) and evaluates the causal effect of pharmacological interventions on this rare outcome. Leveraging a longitudinal electronic health record cohort with a 90-day observation window and a 730-day prediction horizon, the work integrates time-series diagnostic, procedural, medication, and renal function data. It proposes a novel causal multi-head model that combines Transformer architecture with counterfactual reasoning to estimate average treatment effects at both drug and ingredient levels. Counterfactual exposure simulations are validated through robustness checks employing inverse probability of treatment weighting (IPTW), augmented IPTW (AIPW), and covariate-adjusted regression. The model achieves an AUC of 0.694 and a PR-AUC of 0.094 on the test set. Causal analyses suggest a potential protective effect of ACE inhibitors/ARBs, whereas loop diuretics may exacerbate renal deterioration.

Technology Category

Application Category

πŸ“ Abstract
Progression to dialysis or end-stage renal disease is a rare but clinically important outcome. Clinicians need evidence on how medication exposures influence downstream risk. We constructed a fixed-window EHR cohort (90-day observation, 730-day prediction; N=81401; dialysis/ESRD prevalence: 1.1%) and modeled sequences of diagnoses, procedures, and medications with kidney laboratory trends (creatinine, BUN, eGFR). A transformer-based causal multi-head model was trained to estimate drug- and ingredient-level average treatment effects (ATEs) using counterfactual exposure removal and insertion under a full medication history setup. On test set, predictive performance reached an AUC of 0.694 and PR-AUC of 0.094. At the selected decision threshold (0.883), the model achieved an F1 score of 0.201 with a Brier score of 0.018. Post-hoc causal analyses of lab changes (eGFR, creatinine, BUN) using IPTW, AIPW, naive, and covariate-adjusted OLS methods assessed clinical directionality. Results showed partial protective-direction support for ACE/ARB exposures and worsening-direction signals for loop diuretics.
Problem

Research questions and friction points this paper is trying to address.

dialysis risk prediction
treatment effect estimation
acute kidney injury
electronic health records
causal inference
Innovation

Methods, ideas, or system contributions that make the work stand out.

Transformer-based causal model
Average Treatment Effect (ATE)
Counterfactual exposure
Longitudinal EHR
Dialysis risk prediction
πŸ”Ž Similar Papers
No similar papers found.
πŸ’Ό Related Jobs
Postdoctoral Fellow – AI-Driven Multi-Omics Integration for Predictive Toxicology
Pfizer
The annual base salary for this position ranges from $64,600.00 to $107,600.00. In addition, this position is eligible for participation in Pfizer’s Global Performance Plan with a bonus target of 7.5% of the base salary. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life’s moments. Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage. Learn more at Pfizer Candidate Site – U.S. Benefits | (uscandidates.mypfizerbenefits.com). Pfizer compensation structures and benefit packages are aligned based on the location of hire. The United States salary range provided does not apply to Tampa, FL or any location outside of the United States. Relocation assistance may be available based on business needs and/or eligibility.
Hybrid
K
Kalyani P. Pande
Stony Brook University, Stony Brook, NY, USA
E
Evan Yang
Stony Brook University, Stony Brook, NY, USA
B
Bryan Zhu
Stony Brook University, Stony Brook, NY, USA
S
Sandeep K. Mallipattu
Stony Brook University, Stony Brook, NY, USA
Alisa Yurovsky
Alisa Yurovsky
Stony Brook Universty
Bioinformatics
Tengfei Ma
Tengfei Ma
Stony Brook University
Natural Language ProcessingMachine LearningHealthcareGraph Neural Networks